Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | hexokinase, putative | 0.0177 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.0177 | 1 | 0.5 |
Onchocerca volvulus | 0.0177 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.0177 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0177 | 1 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.0177 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.0177 | 1 | 0.5 |
Onchocerca volvulus | 0.0177 | 1 | 1 | |
Trypanosoma cruzi | hexokinase, putative | 0.0177 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0177 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0177 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0177 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0177 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0177 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0177 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0177 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0121 | 0.1468 | 0.1468 |
Loa Loa (eye worm) | hexokinase type II | 0.0177 | 1 | 1 |
Echinococcus granulosus | hexokinase type 2 | 0.0177 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0177 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0177 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0177 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0177 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0177 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0177 | 1 | 0.5 |
Plasmodium falciparum | hexokinase | 0.0177 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0177 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0177 | 1 | 1 |
Schistosoma mansoni | hexokinase | 0.0177 | 1 | 0.5 |
Onchocerca volvulus | 0.0177 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 59.2 % | Inhibition of biotinylated VEGF-A165 from rat recombinant NRP-1 Fc domain at 100 uM | ChEMBL. | 24961874 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.